Jazz Pharmaceuticals Joins Growing Number Of Drug Makers Restricting 340B Discounts

As federal lawmakers look to reform aspects of the 340B drug discount program to improve its transparency and oversight, Jazz Pharmaceuticals announced Monday (Sept. 11) it will restrict the eligibility of certain contract pharmacies to receive prescription drugs at 340B discounted prices. Jazz Pharmaceuticals, now the 25th drug maker to restrict how many contract pharmacies can be used by hospitals to dispense 340B drugs, will no longer bill or ship orders of its childhood epilepsy medication Epidolex at 340B prices...